[1] Pillai A, Adilbay D, Matsoukas K, et al. Autoimmune disease and oral squamous cell carcinoma: A systematic review [J]. J Oral Pathol Med, 2021, 50(9):855-863. [2] Rathish D, Wijerathne B, Khan R. Human papillomavirus-associated oral squamous cell carcinoma among adults living in south-central Asia: A systematic review [J]. Indian J Otolaryngol Head Neck Surg, 2022, 74(Suppl 2):1814-1819. [3] Lechner M, Liu J, Masterson L, et al. HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management [J]. Nat Rev Clin Oncol, 2022, 19(5):306-327. [4] Payaradka R, Ramesh PS, Vyas R, et al. Oncogenic viruses as etiological risk factors for head and neck cancers: An overview on prevalence, mechanism of infection and clinical relevance [J]. Arch Oral Biol, 2022, 143: 105526. [5] Benzian H, Watt R, Makino Y, et al. WHO calls to end the global crisis of oral health [J]. Lancet, 2022, 400(10367):1909-1910. [6] Wolff KD, Follmann M, Nast A. The diagnosis and treatment of oral cavity cancer [J]. Dtsch Arztebl Int, 2012, 109(48): 829-835. [7] Membreno PV, Luttrell JB, Mamidala MP, et al. Outcomes of primary radiotherapy with or without chemotherapy for advanced oral cavity squamous cell carcinoma: Systematic review [J]. Head Neck, 2021, 43(10): 3165-3176. [8] Schoenfeld JD, Hanna GJ, Jo VY, et al. Neoadjuvant nivolumab or nivolumab plus ipilimumab in untreated oral cavity squamous cell carcinoma: A phase 2 open-label randomized clinical trial [J]. JAMA Oncol, 2020, 6(10):1563-1570. [9] 崔婧.OSCC的生物信息学分析[D].山东大学,2014. [10] Ahmad P, Nawaz R, Qurban M, et al. Risk factors associated with the mortality rate of oral squamous cell carcinoma patients: A 10-year retrospective study [J]. Medicine, 2021, 100(36): e27127. [11] Vitório JG, Duarte AFF, Dos SFPT, et al. Metabolic landscape of oral squamous cell carcinoma [J]. Metabolomics, 2020, 16(10): 105. [12] 张斅琳,陈小冰,夏娟,等.中国临床试验注册中心口腔类临床研究注册项目的特征分析[J].中华口腔医学杂志,2022,57(9) : 946-952. [13] 宋杲,成梦群.新冠肺炎临床试验注册特点分析:基于美国ClinicalTrials.gov和中国临床研究注册中心数据库[J].中国医药导刊,2020,22(6):369-374. [14] 张婷,殷环,欧阳昭连.基于ClinicalTrials.gov的天然抗肿瘤药临床试验注册特点研究[J].中国新药杂志,2019,28(10):1226-1231. [15] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2018, 68(6): 394-424. [16] Oun R, Moussa YE, Wheate NJ. The side effects of platinum-based chemotherapy drugs: a review for chemists [J]. Dalton Trans, 2018, 47(23): 6645-6653. [17] Wolska-WA, Robak T. Safety and tolerability of antibody-drug conjugates in cancer [J]. Drug Saf, 2019, 42(2):295-314. [18] 肖妍荻,杨华梅,但红霞.抗肿瘤靶向药物相关不良反应在口腔中的表现及处理对策[J].国际口腔医学杂志,2018,45(2):140-144. |